Arax Advisory Partners’s Avanos Medical AVNS Stock Holding History

Arax Advisory Partners’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.9K	Buy	990 +86	+10%	+$1.16K	﹤0.01%	2274
2025 Q4	$10.2K	Sell	904 -12,848	-93%	-$147K	﹤0.01%	2460
2025 Q3	$159K	Buy	13,752 +12,146	+756%	+$142K	﹤0.01%	1348
2025 Q2	$19.7K	Buy	+1,606	New	+$20.2K	﹤0.01%	1675
2024 Q4	–	Sell	-74	Closed	-$1.78K	–	2462
2024 Q3	$1.78K	Hold	74	–	–	﹤0.01%	2105
2024 Q2	$1.48K	Buy	+74	New	+$1.44K	﹤0.01%	2058
2022 Q3	–	Sell	-26	Closed	-$1K	–	1209
2022 Q2	$1K	Hold	26	–	–	﹤0.01%	1006
2022 Q1	$1K	Hold	26	–	–	﹤0.01%	994
2021 Q4	$1K	Hold	26	–	–	﹤0.01%	969
2021 Q3	$1K	Hold	26	–	–	﹤0.01%	876
2021 Q2	$1K	Buy	+26	New	+$1.07K	﹤0.01%	873
2020 Q4	$1K	Hold	26	–	–	﹤0.01%	688
2020 Q3	$1K	Hold	26	–	–	﹤0.01%	654
2020 Q2	$1K	Hold	26	–	–	﹤0.01%	641
2020 Q1	$1K	Hold	26	–	–	﹤0.01%	640
2019 Q4	$1K	Hold	26	–	–	﹤0.01%	560
2019 Q3	$1K	Hold	26	–	–	﹤0.01%	562
2019 Q2	$1K	Buy	+26	New	+$1.11K	﹤0.01%	566

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Arax Advisory Partners's AVNS Position: Q1 2026 in Review

Arax Advisory Partners increased its Avanos Medical (AVNS) stake by 9.5% in Q1 2026, buying an estimated $1.16K and bringing the position to 990 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2274.

Arax Advisory Partners first reported a position in AVNS in Q2 2019 and has held it in 18 quarters since. The position peaked at $159K in Q3 2025. 257 funds tracked by Wall St. Rank hold AVNS as of Q1 2026.

Arax Advisory Partners held 990 shares of Avanos Medical worth $13.9K as of Q1 2026.
Arax Advisory Partners bought 86 Avanos Medical shares in Q1 2026, an estimated $1.16K.
Avanos Medical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2274 holding.
Arax Advisory Partners first reported a position in Avanos Medical in Q2 2019 and has held it in 18 quarters since.
Arax Advisory Partners's Avanos Medical position peaked at $159K in Q3 2025.
257 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.